Clinical trial
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable…
NCT00107341 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00107341 |
|---|---|
| Title | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction |
| Official title | A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for Metastatic Adenocarcinoma of the Lower Esophagus, Gastroesophageal Junction, and Gastric Cardia |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer |
| Intervention type | Drug |
| Interventions | bortezomib, carboplatin, paclitaxel |
| Enrollment | 37 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | May 1, 2008 |
| First posted | Apr 6, 2005 |
| Last update posted | Dec 13, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: